Hemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGM (7634M)
2020年5月13日 - 5:42PM
RNSを含む英国規制内ニュース (英語)
TIDMHEMO
RNS Number : 7634M
Hemogenyx Pharmaceuticals PLC
13 May 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Posting of Annual Report & Notice of Annual General
Meeting
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group, confirms that the Annual Report and Accounts for the year
ended 31 December 2019, the Notice of the Annual General Meeting
("AGM") and a Form of Proxy were posted to shareholders yesterday
and made available on the Company's website:
https://hemogenyx.com/investors/annual-and-half-year-reports .
The AGM is to be held on 4 June 2020 at 8.00 am EST (1.00 pm
BST) at 760 Parkside Ave., Ste. 212, Brooklyn, NY 11226, United
States of America.
COVID-19 Update
The evolving COVID-19 situation and the related UK and US
Government guidelines will clearly impact the ability of the
members of Hemogenyx Pharmaceuticals plc (the "Shareholders" of the
"Company") to attend our AGM. In normal circumstances, the board of
directors of the Company (the "Board") values the opportunity to
meet Shareholders in person. However, following the UK Government's
introduction of stay-at-home measures that require every person
living in the UK to remain at home and prohibit public gatherings
of more than two people and non-essential travel except in specific
circumstances (which do not include attending an AGM), it will not
be possible to hold the AGM in the normal way. Further, in the US,
public health instructions in respect of the evolving situation
regarding COVID-19 and social contact, public gatherings and
non-essential travel are currently in force which also preclude
Shareholders from attending the AGM in person.
The health and safety of our Shareholders and colleagues is
always our utmost priority and therefore it is the Company's
intention to proceed with holding the AGM on 4 June 2020 at 8.00
a.m. EST (1.00 p.m. BST) as a closed meeting and Shareholders and
their proxies will not be able to attend in person. The Company
will make arrangements such that the legal requirements to hold the
AGM and to conduct the business of the AGM can be satisfied through
the attendance of a minimum number of Shareholders (being two
Shareholders). Instead of attending this year's AGM, Shareholders
are asked to exercise their votes by submitting their proxy
electronically or by post, as explained below. Shareholders are
strongly encouraged to only appoint the 'Chairman of the meeting'
as proxy, as no other proxy will be permitted to attend the
meeting.
Should a Shareholder have a question that they would have raised
at the meeting, we ask that they send it by email at least 48 hours
prior to the meeting to headquarters@hemogenyx.com . The Company
will endeavour to publish these questions and the Company's
responses on the Company's website at
https://hemogenyx.com/investors/shareholder-information/ .
The Chairman has exercised his right to demand in advance of the
AGM that voting on all the resolutions will be by poll in
accordance with article 73.2.1 of the articles of association. You
can therefore rest assured that your proxy votes will be counted in
the poll and the resolutions will not be put to the AGM on a show
of hands; this means that your vote is important and does
count.
In the event that the AGM cannot be held as planned, and
depending on Government advice, it is expected that the AGM will
have to be postponed or adjourned to another location and/or date
and time. Shareholders will be notified accordingly through an
announcement via the Regulatory News Service and the Company's
website at https://hemogenyx.com/announcements .
The Board would like to take this opportunity to thank all
Shareholders for their continued support and understanding in these
exceptional circumstances and wish them well during this time as we
all navigate the implications of COVID-19. We look forward to
returning to full Shareholder engagement as soon as reasonably
possible.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Peter Redmond, Non-executive Director Peter.Redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAAJMPTMTJBMLM
(END) Dow Jones Newswires
May 13, 2020 04:42 ET (08:42 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024